Literature DB >> 20145758

Measurement properties of performance-specific pain ratings of patients awaiting total joint arthroplasty as a consequence of osteoarthritis.

Ashley Halket1, Paul W Stratford, Deborah M Kennedy, Linda J Woodhouse, Gregory Spadoni.   

Abstract

PURPOSE: To estimate the test-retest reliability of the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain sub-scale and performance-specific assessments of pain, as well as the association between these measures for patients awaiting primary total hip or knee arthroplasty as a consequence of osteoarthritis.
METHODS: A total of 164 patients awaiting unilateral primary hip or knee arthroplasty completed four performance measures (self-paced walk, timed up and go, stair test, six-minute walk) and the WOMAC. Scores for 22 of these patients provided test-retest reliability data. Estimates of test-retest reliability (Type 2,1 intraclass correlation coefficient [ICC] and standard error of measurement [SEM]) and the association between measures were examined.
RESULTS: ICC values for individual performance-specific pain ratings were between 0.70 and 0.86; SEM values were between 0.97 and 1.33 pain points. ICC estimates for the four-item performance pain ratings and the WOMAC pain sub-scale were 0.82 and 0.57 respectively. The correlation between the sum of the pain scores for the four performance measures and the WOMAC pain sub-scale was 0.62.
CONCLUSION: Reliability estimates for the performance-specific assessments of pain using the numeric pain rating scale were consistent with values reported for patients with a spectrum of musculoskeletal conditions. The reliability estimate for the WOMAC pain sub-scale was lower than typically reported in the literature. The level of association between the WOMAC pain sub-scale and the various performance-specific pain scales suggests that the scores can be used interchangeably when applied to groups but not for individual patients.

Entities:  

Keywords:  WOMAC; arthroplasty; numeric pain rating scale; osteoarthritis; performance measures; reliability

Year:  2008        PMID: 20145758      PMCID: PMC2792776          DOI: 10.3138/physio.60.3.255

Source DB:  PubMed          Journal:  Physiother Can        ISSN: 0300-0508            Impact factor:   1.037


  19 in total

1.  Assessment of the test-retest reliability and construct validity of a modified WOMAC index in knee osteoarthritis.

Authors:  Marc Faucher; Serge Poiraudeau; Marie Martine Lefevre-Colau; François Rannou; Jacques Fermanian; Michel Revel
Journal:  Joint Bone Spine       Date:  2004-03       Impact factor: 4.929

2.  Sample size and optimal designs for reliability studies.

Authors:  S D Walter; M Eliasziw; A Donner
Journal:  Stat Med       Date:  1998-01-15       Impact factor: 2.373

3.  Measurement properties of the WOMAC LK 3.1 pain scale.

Authors:  P W Stratford; D M Kennedy; L J Woodhouse; G F Spadoni
Journal:  Osteoarthritis Cartilage       Date:  2006-10-12       Impact factor: 6.576

4.  Osteoarthritis clinical trials: candidate variables and clinimetric properties.

Authors:  N Bellamy
Journal:  J Rheumatol       Date:  1997-04       Impact factor: 4.666

5.  Effect of encouragement on walking test performance.

Authors:  G H Guyatt; S O Pugsley; M J Sullivan; P J Thompson; L Berman; N L Jones; E L Fallen; D W Taylor
Journal:  Thorax       Date:  1984-11       Impact factor: 9.139

6.  Self-reported physical functioning was more influenced by pain than performance-based physical functioning in knee-osteoarthritis patients.

Authors:  Caroline B Terwee; Rienk M A van der Slikke; Rob C van Lummel; Rob J Benink; Wil G H Meijers; Henrica C W de Vet
Journal:  J Clin Epidemiol       Date:  2006-07       Impact factor: 6.437

7.  Condition-specific Western Ontario McMaster Osteoarthritis Index was not superior to region-specific Lower Extremity Functional Scale at detecting change.

Authors:  Paul W Stratford; Deborah M Kennedy; Steven E Hanna
Journal:  J Clin Epidemiol       Date:  2004-10       Impact factor: 6.437

8.  Reliability and validity of the Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index in Italian patients with osteoarthritis of the knee.

Authors:  F Salaffi; G Leardini; B Canesi; A Mannoni; A Fioravanti; R Caporali; G Lapadula; L Punzi
Journal:  Osteoarthritis Cartilage       Date:  2003-08       Impact factor: 6.576

9.  Translation, adaptation and validation of the Western Ontario and McMaster Universities osteoarthritis index (WOMAC) for an Arab population: the Sfax modified WOMAC.

Authors:  Mohammad Guermazi; Serge Poiraudeau; Monem Yahia; Monia Mezganni; Jacques Fermanian; M Habib Elleuch; Michel Revel
Journal:  Osteoarthritis Cartilage       Date:  2004-06       Impact factor: 6.576

10.  Assessing stability and change of four performance measures: a longitudinal study evaluating outcome following total hip and knee arthroplasty.

Authors:  Deborah M Kennedy; Paul W Stratford; Jean Wessel; Jeffrey D Gollish; Dianne Penney
Journal:  BMC Musculoskelet Disord       Date:  2005-01-28       Impact factor: 2.362

View more
  3 in total

1.  Body weight changes and corresponding changes in pain and function in persons with symptomatic knee osteoarthritis: a cohort study.

Authors:  Daniel L Riddle; Paul W Stratford
Journal:  Arthritis Care Res (Hoboken)       Date:  2013-01       Impact factor: 4.794

2.  A randomised controlled trial for the effectiveness of intra-articular Ropivacaine and Bupivacaine on pain after knee arthroscopy: the DUPRA (DUtch Pain Relief after Arthroscopy)-trial.

Authors:  M M Campo; G M M J Kerkhoffs; I N Sierevelt; R R Weeseman; H M Van der Vis; G H R Albers
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2011-06-01       Impact factor: 4.342

3.  A 6-week hip muscle strengthening and lumbopelvic-hip core stabilization program to improve pain, function, and quality of life in persons with patellofemoral osteoarthritis: a feasibility pilot study.

Authors:  Lisa T Hoglund; Laura Pontiggia; John D Kelly
Journal:  Pilot Feasibility Stud       Date:  2018-04-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.